Gene Therapy
Gene Therapy at a Crossroads: What the Sarepta Crisis Reveals — and What Comes Next
David Alvaro, Ph.D.; April Stanley, MS MBA; Sophie Lutter, Ph.D.
Pharma's Almanac
PAO-08-25-NI-02Aug 05, 2025
AAV
Gene Therapy at a Crossroads: Rethinking AAV Amid Industry Resets
Daniel Smith, Ph.D.
Nice Consulting
PAO-05-25-NI-02May 06, 2025
Gene Tools
Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos
David Alvaro, Ph.D.; Jon Moulton, Ph.D.
Pharma's Almanac
PAO-01-23-CL-05Feb 01, 2023
Agreement
Hansa Biopharma Announces Exclusive Agreement with Sarepta Therapeutics to Develop Imlifidase as Pre-treatment Ahead of Gene Therapy
Sarepta Therapeutics, Inc
PR-M07-20-NI-004Jul 03, 2020
Leadership
Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors
Sarepta Therapeutics, Inc
PR-M01-20-NI-033Jan 21, 2020
CDMO
Yposkesi Selected to Produce Clinical and Large-Scale Commercial Material of Micro-Dystrophin for Genethon and Sarepta Therapeutics Program
Yposkesi
PR-M01-20-NI-015-1807Jan 09, 2020